Geneseeq Technology Inc. published a collaborative study in Cell Communication and Signaling featuring a lymphoma-specific application of Fragmentia-AI™ Lymphoma, a transformer-based genomic language model enabling lymphoma detection using ultra-low-pass whole-genome sequencing.

Geneseeq Technology Inc. is a research-driven global leader in precision oncology, advancing cancer detection, diagnosis, and treatment through cutting-edge next-generation sequencing (NGS) technologies. With headquarters in Canada and China, Geneseeq operates CAP-, CLIA-, and ISO 15189-accredited laboratories for central laboratory testing, and is ISO 13485-certified for the development and manufacturing of both in vitro diagnostic (IVD) and research use only (RUO) testing kits. Our comprehensive testing portfolio includes: -Pan-cancer panels covering over 400 genes; including GeneseeqPrime®, which is FDA-cleared, CE-IVD marked, and NMPA-approved; -Cancer-type-specific panels tailored for solid tumors and hematologic malignancies; -Minimal residual disease (MRD) monitoring technologies; -Multi-cancer early detection (MCED) solutions, including CanScan®, which holds both CE mark and FDA Breakthrough Device Designation; -CE-IVD and NMPA-approved NGS-based assays, including tumor mutational burden (TMB) testing. Geneseeq’s testing services and products are widely adopted by more than 8,000 oncologist partners across 20+ countries and regions. We are actively involved in over 2,700 research collaborations with pharmaceutical and academic partners, providing high-quality genomic data to support biomarker discovery, clinical development, and translational research. Driven by innovation and a commitment to quality, Geneseeq delivers integrated NGS solutions that help guide personalized treatment decisions and accelerate the global adoption of precision cancer care.

Founded 2012